# US 2026/0085073 A1 · Pyrazolylcarboxamide compounds and their use in therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0085073 A1
- Document ID: US20260085073A1
- Status: Published application
- Kind: A1
- Application number: 19/110,200
- Filed: 2023-09-12
- Published: 2026-03-26
- Earliest claimed: 2022-09-12
- Assignees: Hotspot Therapeutics, Inc.
- Applicants: Hotspot Therapeutics, Inc.
- Inventors: Kenneth G. Carson; Geraldine Cirillo Harriman; Arwel Lewis; Gabriele Fumagalli; Benjamin Paul Whittaker; Alison Jones; Robert Stuart Laurie Chapman; Maria Angel Palomero-Vazquez; Riccardo Guareschi; Christopher James Lock; James Henry Lewis; Antonio Dore; Alicia Jayne Carey
- Web page: https://patentgrep.com/patent/US20260085073A1

## CPC

- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07D 495/04: Ortho-condensed systems
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/502: ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A61K 31/5025: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5365: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/538: ortho- or peri-condensed with carbocyclic ring systems
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07B 59/002: {Heterocyclic compounds}
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 491/044: with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D 491/048: the oxygen-containing ring being five-membered
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 498/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention provides pyrazolylcarboxamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein I (MALT1), and their use in the treatment of a disease or condition, such as a proliferative disorder, inflammatory disorder, or autoimmune disorder.

## Claims

### Claim 1

A compound represented by Formula I:
or a pharmaceutically acceptable salt thereof; wherein:
A1 is phenyl or a 6 membered heteroaryl containing 1 or 2 nitrogen atoms, wherein the phenyl and heteroaryl are substituted with m occurrences of R5 and n occurrences of R6;
A2 is a 5-7 membered partially unsaturated ring containing 0, 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, or a 5-7 membered saturated or partially unsaturated oxo-substituted ring containing 0, 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur;
A3 represents independently for each occurrence a 4-6 membered saturated heterocyclyl containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is substituted with y occurrences of R12,
R1 is hydrogen or C1-4 alkyl;
R2 is C1-6 alkyl, C1-6 haloalkyl, C1-6 deuteroalkyl, C1-6 hydroxyalkyl, C3-7 cycloalkyl, —(C1-6 alkylene)-N(R8) (R9), —(C1-6 alkylene)-C1-6 alkoxyl, or a 3-5 membered saturated heterocyclyl containing 1 or 2 heteroatoms independently selected from oxygen and nitrogen; or R2 and R1 are taken together with their intervening atoms to form a 5-7 membered ring containing 2 nitrogen atoms; or R2 and one occurrence of R7 are taken together with their intervening atoms to form a 5-7 membered ring containing 1 nitrogen atom;
R3 is C1-6 haloalkyl, C1-6 alkyl, or hydrogen;
R4 is phenyl, a 5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, a 9-10 membered bicyclic heteroaryl containing 1, 2, 3, or 4 heteroatoms independently selected from oxygen, nitrogen, and sulfur, a 3-10 membered monocyclic or bicyclic saturated or partially unsaturated heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur,
wherein the phenyl, heteroaryl,
are substituted with t occurrences of R7;
R5 is —C(O)—N(R9)(R10) or a 5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heteroaryl is substituted with q occurrences of R12;
R6 represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyl, C3-7 cycloalkyl, cyano, —O—C3-7 cycloalkyl, —N(R9)(R10), —(C0-4 alkylene)-C(O)R8, —C(O)N(R9)(R10), —N(R9)C(O)R11, or —SO2R11;
R7 represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyl, C3-7 cycloalkyl, cyano, —O—C3-7 cycloalkyl, —(C0-4 alkylene)-CN, —(C1-4 alkylene)-(C1-6 alkoxyl), C2-4 alkynyl, —N(R9)(R10), —(C0-4 alkylene)-C(O)R8, —C(O)N(R9)(R10), —N(R9)C(O)R11, —SO2R11, or —O-A3;
R8 is —OH, —O—(C1-6 alkyl), —O—C3-7 cycloalkyl, or A3;
R9 and R10 are independently hydrogen, C1-6 alkyl, or C3-7 cycloalkyl, or R9 and R10 are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring containing 1 nitrogen atom, wherein the heterocyclic ring is substituted with 0 or 1 groups independently selected from hydroxyl, halo, and C1-6 alkyl;
R11 represents independently for each occurrence C1-6 alkyl or (C0-5 alkylene)-C3-7 cycloalkyl;
R12 represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyl, or C3-7 cycloalkyl;
X is a bond, C1-5 alkylene, C3-5 cycloalkylene, C2-4 alkenylene, —(C0-2 alkylene)-O—(C0-2 alkylene)-, —(C0-2 alkylene)-N(R9)—(C0-2 alkylene)-, or —C(O)—; and
m, n, q, t, and y are independently 0, 1, or 2;
provided that R2 and R3 are not simultaneously C1-4 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula I.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, wherein R3 is C1-6 haloalkyl.

### Claim 4 (depends on 1, 2)

The compound of claim 1 or 2, wherein R3 is —CF3.

### Claim 5 (depends on 1, 2)

The compound of claim 1 or 2, wherein R3 is C1-6 alkyl.

### Claim 6 (depends on 1, 2)

The compound of claim 1 or 2, wherein R3 is methyl.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein the compound is a compound of Formula Ia or a pharmaceutically acceptable salt thereof:

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The compound of any one of claims 1-6, wherein the compound is a compound of Formula Ib or a pharmaceutically acceptable salt thereof:

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein R1 is hydrogen.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, wherein R1 is C1-4 alkyl.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, wherein X is a bond.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, wherein X is C1-5 alkylene or C3-5 cycloalkylene.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, wherein X is C2-4 alkenylene, —(C0-2 alkylene)-O—(C0-2 alkylene), or —(C0-2 alkylene)-N(R9)—(C0-2 alkylene).

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The compound of any one of claims 1-13, wherein A1 is pyridinyl substituted with m occurrences of R5 and n occurrences of R6.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula Ic or a pharmaceutically acceptable salt thereof:

### Claim 16 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula Id or a pharmaceutically acceptable salt thereof:

### Claim 17 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula Ie or a pharmaceutically acceptable salt thereof:

### Claim 18 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula If or a pharmaceutically acceptable salt thereof:

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, wherein R4 is phenyl substituted with t occurrences of R7.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, wherein R4 is a 5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heteroaryl is substituted with t occurrences of R7.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, wherein R4 is pyridinyl substituted with t occurrences of R7.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, wherein R4 is a 9-10 membered bicyclic heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heteroaryl is substituted with t occurrences of R7.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, wherein R4 is a 3-10 membered monocyclic or bicyclic saturated or partially unsaturated heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is substituted with t occurrences of R7.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, wherein R4 is
each of which are substituted with t occurrences of R7.

### Claim 25 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula Ig, Ih, Ii, or Ij or a pharmaceutically acceptable salt thereof:

### Claim 26 (depends on 1)

The compound of claim 1, wherein the compound is a compound of Formula Ik, Il, Im, or In or a pharmaceutically acceptable salt thereof:

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The compound of any one of claims 1-26, wherein R7 represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyl, or C3-7 cycloalkyl.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The compound of any one of claims 1-26, wherein R7 represents independently for each occurrence halo, C1-6 alkyl, cyano, —O—C3-7 cycloalkyl, —(C0-4 alkylene)-CN, —(C1-4 alkylene)-(C1-6 alkoxyl), C2-4 alkynyl, or —N(R9)(R10).

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The compound of any one of claims 1-26, wherein R7 represents independently for each occurrence halo, C1-6 alkyl, —(C0-4 alkylene)-C(O)R8, —C(O)N(R9)(R10), —N(R9)C(O)R11, —SO2R11, or —O-A3.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound of any one of claims 1-29, wherein t is 1.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The compound of any one of claims 1-26, wherein t is 0.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 1-31, wherein R2 is C1-6 alkyl.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 1-31, wherein R2 is methyl.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound of any one of claims 1-33, wherein R5 is a 5 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heteroaryl is substituted with q occurrences of R12.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound of any one of claims 1-33, wherein R5 is a 1,2,3-triazolyl, pyrazolyl, oxazolyl, imidazolyl, isoxazolyl, pyrrolyl, or furanyl, each of which substituted with q occurrences of R12.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The compound of any one of claims 1-33, wherein R5 is a 1,2,3-triazolyl substituted with q occurrences of R12.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The compound of any one of claims 1-36, wherein q is 0.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The compound of any one of claims 1-37, wherein R6 represents independently for each occurrence halo, C1-6 alkyl, or C1-6 haloalkyl.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The compound of any one of claims 1-37, wherein R6 is chloro.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The compound of any one of claims 1-37, wherein R6 is C1-6 haloalkyl.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The compound of any one of claims 1-37, wherein R6 is —CF3.

### Claim 42

A compound represented by Formula II:
or a pharmaceutically acceptable salt thereof; wherein:
A1 is a 6 membered heteroaryl containing 1 or 2 nitrogen atoms, wherein the heteroaryl is substituted with m occurrences of R5 and n occurrences of R6;
R1 is hydrogen or C1-4 alkyl;
R2 is C1-6 alkyl, C1-6 haloalkyl, C1-6 deuteroalkyl, C1-6 hydroxyalkyl, or C3-7 cycloalkyl;
R3 represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyl, or C3-7 cycloalkyl;
R4 and R7 are independently hydrogen, C1-6 alkyl, or C3-7 cycloalkyl, or R4 and R7 are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring containing 1 nitrogen atom;
R5 is a 5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heteroaryl is substituted with q occurrences of R8;
R6 represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyl, C3-7 cycloalkyl, cyano, —O—C3-7 cycloalkyl, or —N(R4)(R7);
R8 represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyl, or C3-7 cycloalkyl;
X is a C1-7 bivalent straight or branched saturated hydrocarbon chain wherein 1 or 2 methylene units of the chain are independently and optionally replaced with O; and
m, n, and q are independently 0, 1, or 2.

### Claim 43 (depends on 42)

The compound of claim 42, wherein the compound is a compound of Formula II.

### Claim 44 (depends on 42, 43)

The compound of claim 42 or 43, wherein A1 is pyridinyl substituted with m occurrences of R5 and n occurrences of R6.

### Claim 45 (depends on 42, 43, 44)

The compound of any one of claims 42-44, wherein R5 is a 5 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heteroaryl is substituted with q occurrences of R8.

### Claim 46 (depends on 42, 43, 44)

The compound of any one of claims 42-44, wherein R5 is 1,2,3-triazolyl, pyrazolyl, oxazolyl, imidazolyl, isoxazolyl, pyrrolyl, or furanyl, each of which substituted with q occurrences of R8.

### Claim 47 (depends on 42, 43, 44)

The compound of any one of claims 42-44, wherein R5 is 1,2,3-triazolyl substituted with q occurrences of R8.

### Claim 48 (depends on 42, 43, 44, 45, 46, 47)

The compound of any one of claims 42-47, wherein q is 0.

### Claim 49 (depends on 42, 43, 44, 45, 46, 47, 48)

The compound of any one of claims 42-48, wherein m is 1.

### Claim 50 (depends on 42, 43, 44)

The compound of any one of claims 42-44, wherein m is 0.

### Claim 51 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50)

The compound of any one of claims 42-50, wherein n is 1.

### Claim 52 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 42-51, wherein R6 represents independently for each occurrence halo, C1-6 alkyl, or C1-6 haloalkyl.

### Claim 53 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 42-51, wherein R6 is chloro.

### Claim 54 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 42-51, wherein R6 is C1-6 haloalkyl.

### Claim 55 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The compound of any one of claims 42-51, wherein R6 is —CF3.

### Claim 56 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The compound of any one of claims 42-52, wherein R1 is hydrogen

### Claim 57 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound of any one of claims 42-56, wherein R2 is C1-6 alkyl.

### Claim 58 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound of any one of claims 42-56, wherein R2 is methyl.

### Claim 59 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The compound of any one of claims 42-58, wherein X is —CH2CH2— or —CH2CH2CH2—.

### Claim 60 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The compound of any one of claims 42-58, wherein X is —CH2CH2CH2— wherein one CH2 is replaced with —O—.

### Claim 61

A compound represented by Formula III:
or a pharmaceutically acceptable salt thereof, wherein:
A1 is phenyl or a 6 membered heteroaryl containing 1 or 2 nitrogen atoms, wherein the phenyl and heteroaryl are substituted with m occurrences of R5 and n occurrences of R6;
A2 is a 5-7 membered partially unsaturated ring containing 0, 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, or a 5-7 membered partially unsaturated oxo-substituted ring containing 0, 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur;
A3 represents independently for each occurrence a 4-6 membered saturated heterocyclyl containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is substituted with y occurrences of R12;
R1 is hydrogen or C1-4 alkyl;
R2 is C1-6 alkyl, C1-6 haloalkyl, C1-6 deuteroalkyl, C1-6 hydroxyalkyl, C3-7 cycloalkyl, —(C1-6 alkylene)-N(R8)(R9), —(C1-6 alkylene)-C1-6 alkoxyl, or a 3-5 membered saturated heterocyclyl containing 1 or 2 heteroatoms independently selected from oxygen and nitrogen; or R2 and R1 are taken together with their intervening atoms to form a 5-7 membered ring containing 2 nitrogen atoms; or R2 and one occurrence of R7 are taken together with their intervening atoms to form a 5-7 membered ring containing 1 nitrogen atom;
R3 is C1-6 haloalkyl, C1-6 alkyl, or hydrogen;
R4 is phenyl, a 5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, a 9-10 membered bicyclic heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, a 3-10 membered monocyclic or bicyclic saturated or partially unsaturated heterocyclyl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur,
wherein the phenyl, heteroaryl,
are substituted with t occurrences of R7;
R5 is a 5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heteroaryl is substituted with q occurrences of R12;
R6 represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyl, C3-7 cycloalkyl, cyano, —O—C3-7 cycloalkyl, —N(R9)(R10), —(C0-4 alkylene)-C(O)R8, —C(O)N(R9)(R10), —N(R)C(O)R11, or —SO2R11;
R7 represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 alkoxyl, C3-7 cycloalkyl, cyano, —O—C3-7 cycloalkyl, —(C0-4 alkylene)-CN, —(C1-4 alkylene)-(C1-6 alkoxyl), C2-4 alkynyl, —N(R9)(R10), —(C0-4 alkylene)-C(O)R8, —C(O)N(R9)(R10), —N(R9)C(O)R11, —SO2R11, or —O-A3;
R8 is —OH, —O—(C1-6 alkyl), —O—C3-7 cycloalkyl, or A3;
R9 and R10 are independently hydrogen, C1-6 alkyl, or C3-7 cycloalkyl, or R9 and R10 are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring containing 1 nitrogen atom, wherein the heterocyclic ring is substituted with 0 or 1 groups independently selected from hydroxyl, halo, and C1-6 alkyl;
R11 represents independently for each occurrence C1-6 alkyl or (C0-5 alkylene)-C3-7 cycloalkyl;
R12 represents independently for each occurrence halo, hydroxyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxyl, or C3-7 cycloalkyl;
X is a bond, C1-5 alkylene, C3-5 cycloalkylene, C2-4 alkenylene, —(C0-2 alkylene)-O—(C0-2 alkylene), —(C0-2 alkylene)-N(R9)—(C0-2 alkylene), or —C(O)—; and
m, n, q, t, and y are independently 0, 1, or 2;
provided that R2 and R3 are not simultaneously C1-4 alkyl.

### Claim 62 (depends on 61)

The compound of claim 61, wherein the compound is a compound of Formula III.

### Claim 63 (depends on 61, 62)

The compound of claim 61 or 62, wherein R3 is C1-6 haloalkyl.

### Claim 64 (depends on 61, 62)

The compound of claim 61 or 62, wherein R3 is —CF3.

### Claim 65 (depends on 61, 62)

The compound of claim 61 or 62, wherein R3 is C1-6 alkyl.

### Claim 66 (depends on 61, 62)

The compound of claim 61 or 62, wherein R3 is methyl.

### Claim 67 (depends on 61, 62, 63, 64, 65, 66)

The compound of any one of claims 61-66, wherein A1 is pyridinyl substituted with m occurrences of R5 and n occurrences of R6.

### Claim 68 (depends on 61, 62, 63, 64, 65, 66, 67)

The compound of any one of claims 61-67, wherein R4 is phenyl substituted with t occurrences of R7.

### Claim 69 (depends on 61, 62, 63, 64, 65, 66, 67)

The compound of any one of claims 61-67, wherein R4 is a 5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heteroaryl is substituted with t occurrences of R7.

### Claim 70 (depends on 61, 62, 63, 64, 65, 66, 67)

The compound of any one of claims 61-67, wherein R4 is a 9-10 membered bicyclic heteroaryl containing 1, 2, or 3 heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein the heteroaryl is substituted with t occurrences of R7.

### Claim 71

A compound in Table 1, 2, or 3, or a pharmaceutically acceptable salt thereof.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

A pharmaceutical composition comprising a compound of any one of claims 1-71 and a pharmaceutically acceptable carrier.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

A method for treating a disease or condition mediated by MALT1, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-71 to treat the disease or condition.

### Claim 74 (depends on 73)

The method of claim 73, wherein said disease or condition mediated by MALT1 is a proliferative disorder.

### Claim 75 (depends on 73)

The method of claim 73, wherein said disease or condition mediated by MALT1 is an inflammatory disorder.

### Claim 76 (depends on 73)

The method of claim 73, wherein said disease or condition mediated by MALT1 is an autoimmune disorder.

### Claim 77 (depends on 73)

The method of claim 73, wherein said disease or condition mediated by MALT1 is selected from cancer, neoplasia, chronic inflammatory disorder, acute inflammatory disorder, auto-inflammatory disorder, autoimmune disorder, fibrotic disorder, metabolic disorder, cardiovascular disorder, cerebrovascular disorder, myeloid cell-driven hyper-inflammatory response in COVID-19 infection, and a combination thereof.

### Claim 78 (depends on 73)

The method of claim 73, wherein said disease or condition mediated by MALT1 is cancer.

### Claim 79 (depends on 78)

The method of claim 78, wherein the cancer is lung cancer, pancreatic cancer, colorectal cancer, breast cancer, cervical cancer, prostate cancer, gastric cancer, skin cancer, liver cancer, bile duct cancer, nervous system cancer, a lymphoma, or a leukemia.

### Claim 80 (depends on 78)

The method of claim 78, wherein the cancer is a lymphoma or leukemia.

### Claim 81 (depends on 78)

The method of claim 78, wherein the cancer is a B-cell lymphoma or chornic myelocytic leukemia.

### Claim 82 (depends on 73)

The method of claim 73, wherein said disease or condition mediated by MALT1 is Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphoma (DLBCL), MALT lymphoma, germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL), primary mediastinal B-cell lymphoma (PMBL), or activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL).

### Claim 83 (depends on 73)

The method of claim 73, wherein said disease or condition mediated by MALT1 is multiple sclerosis, ankylosing spondylitis, arthritis, osteoarthritis, juvenile arthritis, reactive arthritis, rheumatoid arthritis, psoriatic arthritis, acquired immunodeficiency syndrome (AIDS), Coeliac disease, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn's disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenia thrombotic purpura, myasthenia gravis, Sjogren's syndrome, scleroderma, ulcerative colitis, asthma, uveitis, rosacea, dermatitis, alopecia areata, vitiligo, arthritis, Type 1 diabetes, lupus erythematosus, systemic lupus erythematosus, Hashimoto's thyroiditis, myasthenia gravis, nephrotic syndrome, eosinophilia fasciitis, hyper IgE syndrome, lepromatous leprosy, sezary syndrome, idiopathic thrombocytopenia purpura, restenosis following angioplasty, a tumor, or artherosclerosis.

### Claim 84 (depends on 73)

The method of claim 73, wherein said disease or condition mediated by MALT1 is allergic rhinitis, nasal inflammation, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, emphysema, chronic eosinophilic pneumonia, adult respiratory distress syndrome, sinusitis, allergic conjunctivitis, idiopathic pulmonary fibrosis, atopic dermatitis, asthma, allergic rhinitis, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, endometriosis, eczema, psoriasis, rosacea, or lupus erythematosus.

### Claim 85 (depends on 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The method of any one of claims 73-84, wherein the subject is a human.

### Claim 86 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

A method of inhibiting the activity of MALT1, comprising contacting a MALT1 with an effective amount of a compound of any one of claims 1-71 to inhibit the activity of said MALT1.
